(NASDAQ: PTGX) Protagonist Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.66%.
Protagonist Therapeutics's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast PTGX's revenue for 2023 to be $3,172,296,710, with the lowest PTGX revenue forecast at $2,883,906,100, and the highest PTGX revenue forecast at $3,460,687,320. On average, 2 Wall Street analysts forecast PTGX's revenue for 2024 to be $1,441,953,050, with the lowest PTGX revenue forecast at $865,171,830, and the highest PTGX revenue forecast at $2,018,734,270.
In 2025, PTGX is forecast to generate $4,056,675,355 in revenue, with the lowest revenue forecast at $346,068,732 and the highest revenue forecast at $7,498,155,860.